Company: SXTPW
Filing Date: 2025-09-02
Form Type: DEFR14A
Source: 0001213900-25-082789
Chunk: 21

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-02
Form: DEFR14A
Chunk 21
---
. The Code applies to our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The Code is available on our corporate website at https://investors.60degreespharma.com/corporate-governance/governance-overview. The Code requires compliance with applicable law, discusses how conflicts of interest are handled, requires familiarity with the Company’s disclosure requirements and provides for waivers under certain circumstances. We intend to disclose any amendments to our code of business conduct and ethics, or waivers of its requirements, on our website or in filings under the Exchange Act to the extent required by applicable rules and exchange requirements. Board Leadership The Nominating and Corporate Governance Committee annually reviews the Board’s leadership structure and evaluates the performance and effectiveness of the Board. The Board retains the authority to modify its leadership structure in order to stay current with our Company’s circumstances and advance the best interests of the Company and its stockholders as and when appropriate. The Board’s annual self-evaluation includes questions regarding the Board’s opportunities for open communication and the effectiveness of executive sessions. Corporate Governance Policies and Practices Director Independence. The Board undertakes an annual review of director independence. During this review, the Board considers transactions and relationships between each director or any member of his or her immediate family and the Company and its subsidiaries and affiliates. The purpose of this review is to determine whether any such relationships or transactions were inconsistent with a determination that the director is independent. As a result of this review, the Board affirmatively determined that three (3) of the five (5) of the directors are independent of the Company and its management under Nasdaq rules. Geoffrey Dow and Cheryl Xu are not considered independent because of their employment by the Company. 12 In determining that the other directors did not have a material relationship with the Company, the Board concluded that Messrs. Allen, Toovey and Field had no other relationship with the Company other than their relationship as a director. Board Committee Charters. The Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee of the Board operate pursuant to written charters. These charters were approved by the Board and reflect certain best practices in corporate governance. These charters comply with the requirements of the Nasdaq. Each charter is available on the Company’s website at: https://investors.60degreespharma.com/corporate-governance/governance-overview. Private Executive Sessions. Our non-management directors meet in executive session at each